Alexander M Lesokhin
Overview
Explore the profile of Alexander M Lesokhin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
7963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Costa B, Flynn J, Nishimura N, Devlin S, Farzana T, Rajeeve S, et al.
Blood Cancer J
. 2024 May;
14(1):84.
PMID: 38802346
Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids...
12.
Cirrincione A, Poos A, Ziccheddu B, Kaddoura M, Bartsch M, Maclachlan K, et al.
Blood
. 2024 May;
144(7):771-783.
PMID: 38728430
Acquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IgH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these...
13.
Firestone R, Socci N, Shekarkhand T, Zhu M, Qin W, Hultcrantz M, et al.
Blood
. 2024 May;
144(4):402-407.
PMID: 38728378
B-cell maturation antigen (BCMA)-targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how the identification of...
14.
Howard A, Concepcion I, Wang A, Hamadeh I, Hultcrantz M, Mailankody S, et al.
Blood Adv
. 2024 Apr;
8(12):3246-3253.
PMID: 38621239
Outcomes for patients with relapsed/refractory multiple myeloma (R/RMM) have dramatically improved after the development and now growing utilization of B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy and bispecific...
15.
Hamadeh I, Shekarkhand T, Rueda C, Firestone R, Wang A, Korde N, et al.
Blood Adv
. 2024 Apr;
8(12):3038-3044.
PMID: 38598713
Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study...
16.
Costa B, Ortiz R, Lesokhin A, Richter J
Am J Hematol
. 2024 Jan;
99(4):727-738.
PMID: 38270277
B-cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell...
17.
Castro F, Parikh R, Eustaquio J, Derkach A, Joseph J, Lesokhin A, et al.
Leukemia
. 2023 Dec;
38(2):438-441.
PMID: 38158443
No abstract available.
18.
Joseph J, Hillengass J, Tang L, Lesokhin A, Landgren O, Usmani S, et al.
Blood Adv
. 2023 Dec;
8(3):538-548.
PMID: 38055924
Monoclonal gammopathy of undetermined significance (MGUS), a precursor of multiple myeloma, is associated with shorter lifespan and cardiac, renal, neurologic, and immune-related comorbidities. There is little known about modifiable risk...
19.
Maura F, Boyle E, Coffey D, Maclachlan K, Gagler D, Diamond B, et al.
Nat Cancer
. 2023 Nov;
4(12):1660-1674.
PMID: 37945755
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody, progress prematurely. By integrating tumor whole-genome and microenvironment single-cell RNA...
20.
Firestone R, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, et al.
Blood Adv
. 2023 Oct;
8(7):1600-1611.
PMID: 37878808
Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms...